141 related articles for article (PubMed ID: 32977723)
1. Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach.
Kmeťová Sivoňová M; Tatarková Z; Jurečeková J; Kliment J; Híveš M; Lichardusová L; Kaplán P
Neoplasma; 2021 Jan; 68(1):154-164. PubMed ID: 32977723
[TBL] [Abstract][Full Text] [Related]
2. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
Lin JF; Xu J; Tian HY; Gao X; Chen QX; Gu Q; Xu GJ; Song JD; Zhao FK
Int J Cancer; 2007 Dec; 121(12):2596-605. PubMed ID: 17722004
[TBL] [Abstract][Full Text] [Related]
4. [Nuclear matrix proteins differentially expressed in human prostate cancer cell lines and benign prostatic hyperplasia epithelial cell line].
Sun TC; Xin L; Song LM; Zhou Y; Ning LF; Han LY; Guo Y; Yu HM; Wang HP
Zhonghua Nan Ke Xue; 2012 Jul; 18(7):583-9. PubMed ID: 22994041
[TBL] [Abstract][Full Text] [Related]
5. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
6. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
[TBL] [Abstract][Full Text] [Related]
8. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
9. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
10. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
11. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
[TBL] [Abstract][Full Text] [Related]
12. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
13. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
[TBL] [Abstract][Full Text] [Related]
14. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
[TBL] [Abstract][Full Text] [Related]
15. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
[TBL] [Abstract][Full Text] [Related]
16. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
McLerran D; Grizzle WE; Feng Z; Bigbee WL; Banez LL; Cazares LH; Chan DW; Diaz J; Izbicka E; Kagan J; Malehorn DE; Malik G; Oelschlager D; Partin A; Randolph T; Rosenzweig N; Srivastava S; Srivastava S; Thompson IM; Thornquist M; Troyer D; Yasui Y; Zhang Z; Zhu L; Semmes OJ
Clin Chem; 2008 Jan; 54(1):44-52. PubMed ID: 17981926
[TBL] [Abstract][Full Text] [Related]
17. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
Rehman I; Evans CA; Glen A; Cross SS; Eaton CL; Down J; Pesce G; Phillips JT; Yen OS; Thalmann GN; Wright PC; Hamdy FC
PLoS One; 2012; 7(2):e30885. PubMed ID: 22355332
[TBL] [Abstract][Full Text] [Related]
18. Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia.
Sacca PA; Mazza ON; Scorticati C; Vitagliano G; Casas G; Calvo JC
Cancer Genomics Proteomics; 2019; 16(1):29-58. PubMed ID: 30587498
[TBL] [Abstract][Full Text] [Related]
19. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
